NASDAQ
ABEO
Last Price
US $7.06
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Abeona Therapeutics Inc. cash flow to debt ratio of -305.70% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Abeona Therapeutics Inc.'s free cash flow has decreased 44.20% from $-58.46M last year to $-84.30M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Abeona Therapeutics Inc.'s debt to equity ratio is 0.16, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Abeona Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.52 last year to 0.16 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Abeona Therapeutics Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Abeona Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Abeona Therapeutics Inc. has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Abeona Therapeutics Inc.'s short-term assets of $204.91M exceed its short-term liabilities of $29.57M
Increasing performance - ROA.
Abeona Therapeutics Inc.'s return on assets of 33.32% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Abeona Therapeutics Inc.'s return on equity of 41.40%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Abeona Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Abeona Therapeutics Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Abeona Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Abeona Therapeutics Inc. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Abeona Therapeutics Inc.'s yearly earnings has increased -211.69% since last year from $-63.73M to $71.18M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Abeona Therapeutics Inc.'s yearly revenue has increased % since last year from $0.00 to $5.82M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -50.87% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Abeona Therapeutics Inc.'s 3-year revenue CAGR of 60.26% is positive, indicating growing revenue over the past 3 years
Decreasing performance - Revenue consistency.
Abeona Therapeutics Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Abeona Therapeutics Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Abeona Therapeutics Inc. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Abeona Therapeutics Inc. has an earnings yield of 16.55%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Abeona Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Abeona Therapeutics Inc. has an EV/EBITDA ratio of 4.44x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Abeona Therapeutics Inc. has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Abeona Therapeutics Inc. has a price-to-book ratio of 2.76x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Abeona Therapeutics Inc. has a price-to-sales ratio of 27.49x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
41.40%
Return on equity
ROIC: -50.87%
Valuation History
5.4X
Price to Earnings
EV/EBITDA: 4.9X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-15.48%
(FY vs FY)
Fair Value
Market $7.06
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.